Antifibrinolytics

ANI Pharmaceuticals Announces Approval and Launch of Aminocaproic Acid Tablets

Retrieved on: 
Thursday, December 17, 2020
Biotechnology, FDA, Health, Pharmaceutical, Oncology, Aminocaproic acid, Antifibrinolytics, Pharmaceutical companies, Fibrinolysis, Aminocaproic Acid Tablets USP, ANI

ANI Pharmaceuticals, Inc. (ANI or the Company) (Nasdaq: ANIP) today announced U.S. Food and Drug Administration (FDA) approval and the launch of Aminocaproic Acid Tablets USP, 500mg.

Key Points: 
  • ANI Pharmaceuticals, Inc. (ANI or the Company) (Nasdaq: ANIP) today announced U.S. Food and Drug Administration (FDA) approval and the launch of Aminocaproic Acid Tablets USP, 500mg.
  • This important therapeutic is one of the pipeline generic products we acquired from Amerigen Pharmaceuticals, Ltd. earlier this year.
  • Aminocaproic Acid Tablets are useful in enhancing hemostasis when fibrinolysis contributes to bleeding.
  • ANI Pharmaceuticals, Inc. is an integrated specialty pharmaceutical company developing, manufacturing, and marketing branded and generic prescription pharmaceuticals.

Mylan Initiates Voluntary Nationwide Recall of Four Lots of Amiodarone HCl Injection, USP and Tranexamic Acid Injection, USP Due to Carton Label Mix-Up

Retrieved on: 
Friday, August 28, 2020
RTT, Drugs, Medical specialties, Chemical compounds, Antifibrinolytics, Transfusion medicine, Antiarrhythmic agents, Tranexamic acid, Amiodarone

These batches are being recalled due to the potential for cartons labeled as Tranexamic Acid Injection, USP to contain vials of Amiodarone HCl Injection, USP and cartons labeled as Amiodarone HCl Injection, USP to contain vials of Tranexamic Acid Injection, USP.

Key Points: 
  • These batches are being recalled due to the potential for cartons labeled as Tranexamic Acid Injection, USP to contain vials of Amiodarone HCl Injection, USP and cartons labeled as Amiodarone HCl Injection, USP to contain vials of Tranexamic Acid Injection, USP.
  • The individual vials contained within the cartons are accurately labeled as Amiodarone HCl Injection, USP or Tranexamic Acid Injection, USP.
  • Amiodarone HCl Injection, USP and Tranexamic Acid Injection, USP are used to treat different conditions.
  • If treatment with Tranexamic Acid Injection, when needed, is delayed this could result in limited to serious and life-threatening bleeding events.

Tranexamic Acid (CAS 1197-18-8) Market Research Report 2020 - ResearchAndMarkets.com

Retrieved on: 
Tuesday, August 4, 2020
Professional services, Consulting, Transfusion medicine, Antifibrinolytics, RTT, Tranexamic acid, Market research, Chemistry

The "Tranexamic Acid (CAS 1197-18-8) Market Research Report 2020" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Tranexamic Acid (CAS 1197-18-8) Market Research Report 2020" report has been added to ResearchAndMarkets.com's offering.
  • This global report is a result of industry experts' diligent work on researching the world market of Tranexamic acid.
  • The report helps to build up a clear view of the market trends and development, identify major players in the industry, and estimate main downstream sectors.
  • The fifth chapter deals with Tranexamic acid market trends and forecast, distinguish Tranexamic acid manufacturers and suppliers.

American Regent Announces the Re-Introduction of Aminocaproic Acid Injection, USP; AP Rated and Therapeutically Equivalent to Amicar®*(1)

Retrieved on: 
Thursday, February 28, 2019
Blood, Body fluids, Anatomy, Fibrinolytic system, Antifibrinolytics, Coagulation system, Fibrinolysis, Aminocaproic acid, Transfusion medicine, Coagulation, Hematuria, Bleeding

Aminocaproic Acid Injection is useful in enhancing hemostasis when fibrinolysis contributes to bleeding.

Key Points: 
  • Aminocaproic Acid Injection is useful in enhancing hemostasis when fibrinolysis contributes to bleeding.
  • Aminocaproic acid should not be used when there is evidence of an active intravascular clotting process.
  • Aminocaproic acid should not be used in hematuria of upper urinary tract origin, unless the possible benefits outweigh the risk.
  • Laboratory Tests: The use of aminocaproic acid should be accompanied by tests designed to determine the amount of fibrinolysis present.